Why the current innovation model is flawed

The capital for funding innovative biotech startups had dramatically decreased in both Europe and the US during the pandemic. Whereas the US investments have returned to similar numbers as before the pandemic, those in Europe have not recovered since. While at the same time the numbers of innovative treatments have remained stable over the last decade, the costs have doubled. This lack of innovation and the lack of funding is posing a serious problem to address increasing unmet medical needs, not only in aging populations but also by the increased threats of bacterial resistance and new viral pandemics. Brain related diseases are becoming the major health burden in developed countries and brain health as a preventive measure but also drug development are significantly underfunded.